Hcw Biologics Inc (HCWB)

$4.04 +0.31 (8.31%)
Market Cap 8.03M
Revenue (ttm) 2.57M
Net Income (ttm) -30.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,168.09%
Debt to Equity Ratio -135.80
Volume 113,800
Avg Vol 2,348,492
Day's Range N/A - N/A
Shares Out 2.15M
Stochastic %K 64%
Beta 0.62
Analysts Strong Sell
Price Target $35.00

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is i...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 842 2024
Fax: 954 842 2037
Address:
2929 North Commerce Parkway, Miramar, United States
highnihilism
highnihilism Oct. 4 at 9:19 AM
$HCWB HCW Biologics market cap: 8.7M | 4.04 +8.3% | opening gap +3.2% | % from open +4.9% | volume 109K | shares float 1.7M | vol/float 0
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 1:10 AM
$WIMI $PIII $MAAS $HCWB !
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:52 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $PIII $MAAS $HCWB $BINI 🚀
0 · Reply
bMagic69
bMagic69 Oct. 1 at 10:49 PM
$HCWB should be hearing about the Nasdaq hearing soon
1 · Reply
VirtualInvestor
VirtualInvestor Sep. 30 at 1:11 PM
$HCWB CSO, Dr. Rhode, participated in our #WhatThisMeans to discuss the Company's positive results from its NHP study for its proprietary second-generation T-Cell Engager program. https://www.youtube.com/watch?v=uMDL1DMTezU
0 · Reply
VirtualInvestor
VirtualInvestor Sep. 30 at 1:10 PM
$HCWB Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program https://investors.hcwbiologics.com/news-releases/news-release-details/hcw-biologics-inc-nasdaq-hcwb-participates-virtual-investor-what
0 · Reply
Red2Profit
Red2Profit Sep. 25 at 6:22 PM
$HCWB Call it a technical analysis hunch to hit 5.85, 6.09, and 7.16.
0 · Reply
RobertJordan878
RobertJordan878 Sep. 22 at 6:39 AM
$HCWB Healthcare technology niche. Thin volume trading. No clear pattern emerging. Avoid.
0 · Reply
oppdealer1982
oppdealer1982 Sep. 21 at 1:50 AM
$HCWB this is going to be $3 Again?
0 · Reply
Romerob2
Romerob2 Sep. 19 at 6:07 PM
$HCWB
0 · Reply
Latest News on HCWB
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Sep 30, 2025, 8:45 AM EDT - 4 days ago

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Sep 18, 2025, 9:15 AM EDT - 16 days ago

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Sep 16, 2025, 8:00 AM EDT - 18 days ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

Aug 25, 2025, 9:53 AM EDT - 5 weeks ago

HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Aug 25, 2025, 8:00 AM EDT - 5 weeks ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 18, 2025, 2:44 PM EDT - 6 weeks ago

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Jun 27, 2025, 7:45 AM EDT - 3 months ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Jun 26, 2025, 7:55 AM EDT - 3 months ago

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

Jun 4, 2025, 8:20 AM EDT - 4 months ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

May 15, 2025, 6:14 PM EDT - 5 months ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

May 13, 2025, 8:01 PM EDT - 5 months ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

May 13, 2025, 8:30 AM EDT - 5 months ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

HCW Biologics Announces 1-for-40 Reverse Stock Split

Apr 1, 2025, 4:35 PM EDT - 6 months ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 28, 2025, 3:30 PM EDT - 6 months ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Mar 6, 2025, 6:55 AM EST - 7 months ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Feb 3, 2025, 7:15 AM EST - 8 months ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Jan 15, 2025, 7:00 AM EST - 9 months ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Dec 23, 2024, 8:10 AM EST - 10 months ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 9:27 PM EST - 11 months ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Why Is Penny Stock HCW Biologics Surging On Monday?

Nov 18, 2024, 10:15 AM EST - 11 months ago

Why Is Penny Stock HCW Biologics Surging On Monday?

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 18, 2024, 7:00 AM EST - 11 months ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 14, 2024, 4:40 PM EST - 11 months ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 23, 2024, 4:30 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 14, 2024, 4:35 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 4:39 PM EDT - 1 year ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Apr 1, 2024, 4:10 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Nov 14, 2023, 7:00 AM EST - 2 years ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Nov 8, 2023, 7:30 AM EST - 2 years ago

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Sep 6, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

Jun 14, 2023, 7:30 AM EDT - 2 years ago

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

May 9, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Apr 27, 2023, 7:40 AM EDT - 2 years ago

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Apr 13, 2023, 7:15 AM EDT - 2 years ago

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

Apr 3, 2023, 8:13 AM EDT - 2 years ago

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 28, 2023, 4:25 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

HCW Biologics Enters CRADA with National Cancer Institute

Dec 8, 2022, 7:55 AM EST - 3 years ago

HCW Biologics Enters CRADA with National Cancer Institute

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Dec 7, 2022, 7:30 AM EST - 3 years ago

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Nov 8, 2022, 7:00 AM EST - 3 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

Nov 7, 2022, 4:45 PM EST - 3 years ago

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

Aug 31, 2022, 9:22 AM EDT - 3 years ago

HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

SMSI

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

Aug 29, 2022, 8:58 AM EDT - 3 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

CASI HSDT

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

Aug 12, 2022, 7:00 AM EDT - 3 years ago

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

Aug 3, 2022, 7:15 AM EDT - 3 years ago

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

May 23, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 13, 2022, 7:15 AM EDT - 3 years ago

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

May 5, 2022, 7:30 AM EDT - 3 years ago

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

HCW Biologics' CEO Hing C. Wong, Ph.D.

Apr 19, 2022, 7:33 AM EDT - 3 years ago

HCW Biologics' CEO Hing C. Wong, Ph.D.

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

Mar 28, 2022, 7:00 AM EDT - 3 years ago

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

highnihilism
highnihilism Oct. 4 at 9:19 AM
$HCWB HCW Biologics market cap: 8.7M | 4.04 +8.3% | opening gap +3.2% | % from open +4.9% | volume 109K | shares float 1.7M | vol/float 0
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 1:10 AM
$WIMI $PIII $MAAS $HCWB !
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:52 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $PIII $MAAS $HCWB $BINI 🚀
0 · Reply
bMagic69
bMagic69 Oct. 1 at 10:49 PM
$HCWB should be hearing about the Nasdaq hearing soon
1 · Reply
VirtualInvestor
VirtualInvestor Sep. 30 at 1:11 PM
$HCWB CSO, Dr. Rhode, participated in our #WhatThisMeans to discuss the Company's positive results from its NHP study for its proprietary second-generation T-Cell Engager program. https://www.youtube.com/watch?v=uMDL1DMTezU
0 · Reply
VirtualInvestor
VirtualInvestor Sep. 30 at 1:10 PM
$HCWB Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program https://investors.hcwbiologics.com/news-releases/news-release-details/hcw-biologics-inc-nasdaq-hcwb-participates-virtual-investor-what
0 · Reply
Red2Profit
Red2Profit Sep. 25 at 6:22 PM
$HCWB Call it a technical analysis hunch to hit 5.85, 6.09, and 7.16.
0 · Reply
RobertJordan878
RobertJordan878 Sep. 22 at 6:39 AM
$HCWB Healthcare technology niche. Thin volume trading. No clear pattern emerging. Avoid.
0 · Reply
oppdealer1982
oppdealer1982 Sep. 21 at 1:50 AM
$HCWB this is going to be $3 Again?
0 · Reply
Romerob2
Romerob2 Sep. 19 at 6:07 PM
$HCWB
0 · Reply
BullseyeStock
BullseyeStock Sep. 19 at 4:20 AM
$GCTK $ZONE $HCWB $ENTO VRME is setting up perfectly for a moonshot. This ticker is known to run massive. Solid DD to back up its rally, right now not many folks knows about this gem, so be early bulls!!!
0 · Reply
cyrusEtrade
cyrusEtrade Sep. 18 at 1:23 PM
$HCWB
0 · Reply
Whiskey1679
Whiskey1679 Sep. 17 at 12:24 AM
Whiskey's Penny Picks out tomorrow by 6:20 am PDT!!! Have a good night folks! AH Gainers: $ELOG $HIND $AZI $UOKA $HCWB
0 · Reply
cyrusEtrade
cyrusEtrade Sep. 16 at 7:09 PM
$HCWB already doubled my investment once time to do it agin.
0 · Reply
cyrusEtrade
cyrusEtrade Sep. 16 at 7:07 PM
$HCWB buying back in
0 · Reply
race2zero
race2zero Sep. 16 at 4:50 PM
$HCWB under $4 very soon
0 · Reply
race2zero
race2zero Sep. 16 at 4:18 PM
$HCWB
0 · Reply
Wasthereeverausecase
Wasthereeverausecase Sep. 16 at 4:05 PM
$HCWB I expect more misery. Perhaps the $3.25 ?
0 · Reply
race2zero
race2zero Sep. 16 at 3:30 PM
$HCWB
0 · Reply
NinjaRai
NinjaRai Sep. 16 at 12:17 PM
$HCWB $PTIX $STKH
0 · Reply
Romerob2
Romerob2 Sep. 16 at 5:00 AM
$HCWB 🚀🚀🚀
0 · Reply
Joby099
Joby099 Sep. 16 at 3:08 AM
$VSTD $AMST $HCWB $SMCI $HUIZ
0 · Reply